221 related articles for article (PubMed ID: 18349265)
1. Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases.
Schwartz GG
Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):478-83. PubMed ID: 18349265
[TBL] [Abstract][Full Text] [Related]
2. [Physiopathology and new therapeutic strategies in the management of bone metastases of prostate cancer].
Lebret T; Méjean A; Houédé N
Prog Urol; 2011 May; 21(5):301-7. PubMed ID: 21514531
[TBL] [Abstract][Full Text] [Related]
3. Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer.
Murray RM; Grill V; Crinis N; Ho PW; Davison J; Pitt P
J Clin Endocrinol Metab; 2001 Sep; 86(9):4133-8. PubMed ID: 11549639
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer and bone metastases: medical treatment.
Clark PE; Torti FM
Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S148-57. PubMed ID: 14600605
[TBL] [Abstract][Full Text] [Related]
5. Expression of parathyroid hormone-related protein and its receptor in bone metastases from prostate cancer.
Iddon J; Bundred NJ; Hoyland J; Downey SE; Baird P; Salter D; McMahon R; Freemont AJ
J Pathol; 2000 Jun; 191(2):170-4. PubMed ID: 10861577
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of tumor metastasis to the bone: challenges and opportunities.
Reddi AH; Roodman D; Freeman C; Mohla S
J Bone Miner Res; 2003 Feb; 18(2):190-4. PubMed ID: 12568395
[TBL] [Abstract][Full Text] [Related]
7. Direct evidence that PTHrP expression promotes prostate cancer progression in bone.
Deftos LJ; Barken I; Burton DW; Hoffman RM; Geller J
Biochem Biophys Res Commun; 2005 Feb; 327(2):468-72. PubMed ID: 15629138
[TBL] [Abstract][Full Text] [Related]
8. The potential role of bisphosphonates in prostate cancer.
Oades GM; Coxon J; Colston KW
Prostate Cancer Prostatic Dis; 2002; 5(4):264-72. PubMed ID: 12627210
[TBL] [Abstract][Full Text] [Related]
9. Accelerated bone resorption, due to dietary calcium deficiency, promotes breast cancer tumor growth in bone.
Zheng Y; Zhou H; Modzelewski JR; Kalak R; Blair JM; Seibel MJ; Dunstan CR
Cancer Res; 2007 Oct; 67(19):9542-8. PubMed ID: 17909065
[TBL] [Abstract][Full Text] [Related]
10. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
11. [Secondary hyperparathyroidism in advanced prostate cancer].
Quirosa Flores S; Varsavsky M; Valle Díaz De La Guardia F; Miján Ortiz JL; Muñoz Torres M; Raya Alvarez E; Zuluaga Gómez A
Endocrinol Nutr; 2010 Mar; 57(3):100-4. PubMed ID: 20362521
[TBL] [Abstract][Full Text] [Related]
12. The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells.
Russell MR; Jamieson WL; Dolloff NG; Fatatis A
Oncogene; 2009 Jan; 28(3):412-21. PubMed ID: 18850002
[TBL] [Abstract][Full Text] [Related]
13. Pamidronate administration improves the secondary hyperparathyroidism due to "Bone Hunger Syndrome" in a patient with osteoblastic metastases from prostate cancer.
Berruti A; Sperone P; Fasolis G; Torta M; Fontana D; Dogliotti L; Angeli A
Prostate; 1997 Dec; 33(4):252-5. PubMed ID: 9397197
[TBL] [Abstract][Full Text] [Related]
14. A synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein can reduce tumor growth, experimental skeletal metastases, and malignancy-associated hypercalcemia.
Shukeir N; Arakelian A; Chen G; Garde S; Ruiz M; Panchal C; Rabbani SA
Cancer Res; 2004 Aug; 64(15):5370-7. PubMed ID: 15289344
[TBL] [Abstract][Full Text] [Related]
15. Parathyroid hormone-related peptide: expression in prostate cancer bone metastases.
Bryden AA; Islam S; Freemont AJ; Shanks JH; George NJ; Clarke NW
Prostate Cancer Prostatic Dis; 2002; 5(1):59-62. PubMed ID: 15195132
[TBL] [Abstract][Full Text] [Related]
16. In vivo models of prostate cancer metastasis to bone.
Singh AS; Figg WD
J Urol; 2005 Sep; 174(3):820-6. PubMed ID: 16093963
[TBL] [Abstract][Full Text] [Related]
17. Bone metastases in prostate cancer: a targeted approach.
Storey JA; Torti FM
Curr Opin Oncol; 2007 May; 19(3):254-8. PubMed ID: 17414645
[TBL] [Abstract][Full Text] [Related]
18. When prostate cancer meets bone: control by wnts.
Emami KH; Corey E
Cancer Lett; 2007 Aug; 253(2):170-9. PubMed ID: 17462819
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
20. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.
Carducci MA; Jimeno A
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6296s-6300s. PubMed ID: 17062717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
